Negative factors weigh on Daiichi Sankyo's bottom line
This article was originally published in Scrip
Daiichi Sankyo has hauled back its net profit forecast for the current fiscal year, pointing to the expected negative impact of foreign exchange losses and tax changes, as it reported a sharp drop in third quarter profit related to provisions by its Indian subsidiary Ranbaxy.
You may also be interested in...
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.